| LDR | | 05215cmm uu200601Ii 4500 |
| 001 | | 000000303295 |
| 005 | | 20230519172939 |
| 006 | | m o d |
| 007 | | cr ||||||||||| |
| 008 | | 140303t20142014dcua ob 100 0 eng |
| 020 | |
▼a 9780309285971
▼q electronic bk. |
| 020 | |
▼a 0309285976
▼q electronic bk. |
| 020 | |
▼z 9780309285964 |
| 020 | |
▼z 0309285968 |
| 035 | |
▼a (OCoLC)871260167 |
| 040 | |
▼a COP
▼c COP
▼d MMU
▼d UCNAP
▼d COO
▼d OCLCO
▼d N$T
▼d 248032 |
| 049 | |
▼a K4RA |
| 050 | 4 |
▼a RC311.1 |
| 060 | 4 |
▼a WF 200 |
| 072 | 7 |
▼a POL
▼x 027000
▼2 bisacsh |
| 072 | 7 |
▼a POL
▼x 019000
▼2 bisacsh |
| 082 | 04 |
▼a 362.19699500947
▼2 23 |
| 111 | 2 |
▼a Global Crisis of Drug-Resistant Tuberculosis and Leadership of the BRICS Countries : Challenges and Opportunities (Workshop)
▼d (2013 :
▼c Beijing, China) |
| 245 | 14 |
▼a The global crisis of drug-resistant tuberculosis and leadership of China and the BRICS
▼h [electronic resource] :
▼b challenges and opportunities : summary of a joint workshop /
▼c by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Science ; Steve Olson, Rebecca A. English, and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies. |
| 264 | 1 |
▼a Washington, D.C. :
▼b National Academies Press,
▼c [2014] |
| 264 | 4 |
▼c 짤2014 |
| 300 | |
▼a 1 online resource (218 pages) :
▼b illustrations (some color) |
| 336 | |
▼a text
▼2 rdacontent |
| 337 | |
▼a computer
▼2 rdamedia |
| 338 | |
▼a online resource
▼2 rdacarrier |
| 504 | |
▼a Includes bibliographical references. |
| 505 | 0 |
▼a Introduction and overview of the workshop -- The challenges and opportunities for the BRICS countries to lead -- Catching up with the microbe -- Drug-resistant TB in China -- Experience with MDR TB in other countries -- Drug-resistant tuberculosis in pediatric populations -- Global perspectives on transmission and infection control -- Rapid diagnostic technologies: status and limitations -- Addressing diagnosis and treatment across the spectrum of drug resistance -- Developing and strengthening the drug supply chain for drug-resistant TB -- Embracing a new vision for research -- What will be required to achieve zero deaths from TB? -- Creating an evidence-based blueprint for action. |
| 520 | |
▼a "Multidrug-resistant tuberculosis (TB) is caused by bacteria resistant to isoniazid and rifampicin, the two most effective first-line anti-TB drugs, originally developed and introduced in the 1950 and 1960s. Since 2008, the Forum on Drug Discovery, Development, and Translation of the Institute of Medicine has hosted or co-hosted six domestic and international workshops addressing the global crisis of drug-resistant TB, with special attention to the BRICS countries - Brazil, Russia, India, China, and South Africa. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS is the summary of a workshop convened to address the current status of drug-resistant TB globally and in China. This report considers lessons learned from high burden countries; highlights global challenges to controlling the spread of drug-resistant strains; and discusses innovative strategies to advance and harmonize local and international efforts to prevent and treat drug-resistant TB. Additionally, the report examines the problem of MDR TB and emergent TB strains that are potentially untreatable with drugs available and considers the critical leadership role of the BRICS countries in addressing the threats and opportunities in drug-resistant TB"--Publisher's description. |
| 588 | |
▼a Description based on online resource; title from electronic title page (National Academies Press, viewed on March 18, 2014). |
| 650 | 0 |
▼a Multidrug-resistant tuberculosis
▼v Congresses. |
| 650 | 0 |
▼a Multidrug-resistant tuberculosis
▼x Prevention
▼v Congresses. |
| 650 | 0 |
▼a Tuberculosis
▼v Congresses. |
| 650 | 0 |
▼a Drug resistance
▼v Congresses. |
| 650 | 12 |
▼a Tuberculosis, Multidrug-Resistant
▼v Congresses. |
| 650 | 22 |
▼a Antitubercular Agents
▼v Congresses. |
| 650 | 22 |
▼a Health Planning
▼v Congresses. |
| 650 | 22 |
▼a Internationality
▼v Congresses. |
| 650 | 7 |
▼a POLITICAL SCIENCE / Public Policy / Social Security.
▼2 bisacsh |
| 650 | 7 |
▼a POLITICAL SCIENCE / Public Policy / Social Services & Welfare.
▼2 bisacsh |
| 655 | 4 |
▼a Electronic books. |
| 700 | 1 |
▼a Olson, Steve,
▼d 1956,
▼e rapporteur. |
| 700 | 1 |
▼a English, Rebecca A.,
▼e rapporteur. |
| 700 | 1 |
▼a Claiborne, Anne B.,
▼e rapporteur. |
| 710 | 2 |
▼a Zhongguo ke xue yuan.
▼b Wei sheng wu yan jiu suo,
▼e issuing body. |
| 710 | 2 |
▼a Institute of Medicine (U.S.).
▼b Forum on Drug Discovery, Development, and Translation,
▼e issuing body. |
| 776 | 08 |
▼i Print version:
▼a Global Crisis of Drug-Resistant Tuberculosis and Leadership of the BRICS Countries : Challenges and Opportunities (Workshop) (2013 : Beijing, China).
▼t Global crisis of drug-resistant tuberculosis and leadership of China and the BRICS.
▼d Washington, D.C. : National Academies Press, [2014]
▼z 9780309285964 |
| 856 | 40 |
▼3 EBSCOhost
▼u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=867773 |
| 938 | |
▼a EBSCOhost
▼b EBSC
▼n 867773 |
| 990 | |
▼a 관리자 |